Frazier Life Sciences Management, L.P.: ERASCA INC (ERAS): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 24,675,188 shares of ERASCA INC (ERAS), worth $399.2M and representing 10.3% of its 13F equity book. Quarter-over-quarter share count change: + 1,945,752 (+8.6%) . The position first appeared in Q2 2024 and has been disclosed across 8 13F-HR filings in Pactolio's tracked window.
- 24,675,188Shares Held (Latest Filing)
- $399.2MReported Market Value (Latest Filing)
- 10.3%Portfolio Weight (% of 13F Equity Book)
- +1,945,752Quarter-over-Quarter Share Change
- +$314.7MQuarter-over-Quarter Value Change
- 24,675,188Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 8 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 24,675,188 | +1,945,752 | +8.6% | $399.2M | 10.3% | $16.2 |
| Q4 2025 | 22,729,436 | 0 | — | $84.6M | 2.3% | $3.7 |
| Q3 2025 | 22,729,436 | 0 | — | $49.6M | 1.5% | $2.2 |
| Q2 2025 | 22,729,436 | +153,585 | +0.7% | $28.9M | 1.2% | $1.3 |
| Q1 2025 | 22,575,851 | +3,184,164 | +16.4% | $30.9M | 1.4% | $1.4 |
| Q4 2024 | 19,391,687 | 0 | — | $48.7M | 2.0% | $2.5 |
| Q3 2024 | 19,391,687 | +3,175,471 | +19.6% | $52.9M | 2.1% | $2.7 |
| Q2 2024 | 16,216,216 | — | — | $38.3M | 1.8% | $2.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a ERAS position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported ERASCA INC (ERAS) on its 13F-HR filing for the period ending 2024-06-30 (Q2 2024). The position has appeared on 8 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in ERAS?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. added 1,945,752 shares of ERAS (+8.6%), bringing the total reported position to 24,675,188 shares at a market value of $399.2M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in ERAS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.